Collaboration
Swedish biotechs Biovitrum AB and Affibody have signed a collaboration agreement with the aim of developing therapies for inflammation and autoimmune diseases.
Biovitrum gains access to the proprietary technology platform of Affibody molecules and to an albumin-binding technology for pharmaceutical development. Affibody molecules are small stable proteins that can have the same effects as large proteins, and in addition have potential efficacy, safety, administration route and price benefits. The albumin-binding technology is designed to enhance the efficacy of biopharmaceuticals by extending their half-life.
The agreement involves a defined protein target and a product license agreement.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
